Convallatoxin ameliorates fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis by targeting IDH1

Key Points

• Convallatoxin notably decreases synovial inflammation and joint destruction in rheumatoid arthritis, enhancing clinical outcomes.
• IDH1 was specifically targeted, leading to a significant reduction in inflammatory markers by approximately 35 percent.
• Assessment using tissue samples shows fibroblast-like synoviocytes are crucial in mediating inflammation in joint conditions.
• These findings suggest a new potential treatment avenue, though further clinical trials are necessary to validate efficacy.